Physician profile
Danielle L Leeper
NPI 1669924817
$4,208.12
in general payments reported to CMS, 2019-2025
15 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $78.00 · 2023: $1,110 · 2024: $1,283 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.13 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,066.10 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $583.23 | 2022-2025 | Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $458.48 | 2023-2025 | Zerbaxa, Pifeltro, Dificid |
| Abbvie INC. | $422.58 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $286.33 | 2023-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $265.28 | 2023-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Astellas Pharma US INC | $244.05 | 2023-2025 | Cresemba |
| Insmed, INC. | $229.78 | 2023-2025 | Arikayce, Brinsupri |
| Theratechnologies INC. | $180.39 | 2022-2024 | Egrifta, Trogarzo |
| Shionogi INC | $160.04 | 2023-2025 | Fetroja |
| Aimmune Therapeutics, INC. | $141.11 | 2024-2025 | Vowst |
| La Jolla Pharmaceutical Company | $71.68 | 2023-2024 | Xerava, Xacduro |
| Janssen Biotech, INC. | $57.05 | 2023 | Symtuza |
| Nestle Healthcare Nutrition INC. | $25.30 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $16.72 | 2025 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Leeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.